USPTO Examiner SULLIVAN DENNIS JOHN - Art Unit 1642

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18427038ANTI-DCLK1 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS OF USE THEREOFJanuary 2024June 2025Allow1601NoNo
18412245COMPOSITIONS AND METHODS COMPRISING SFRP2 ANTAGONISTSJanuary 2024November 2024Allow1000NoNo
18541600COMBINATION THERAPIES FOR TREATING CANCERDecember 2023March 2025Abandon1510NoNo
18459842METHODS FOR TREATING CANCER WITH ANTI-PD-1 ANTIBODIESSeptember 2023February 2025Abandon1800NoNo
18451990TREATMENT OF LAG-3 POSITIVE TUMORSAugust 2023March 2024Allow700NoNo
18330844USE OF an anti-P-selectin antibodyJune 2023April 2025Abandon2301NoNo
18301141USE OF BAZ1B_K426hy AND POLYCLONAL ANTIBODY THEREOF IN PREPARATION OF PRODUCT FOR TUMOR DETECTIONApril 2023August 2024Allow1610YesNo
18161713METHODS OF TREATING A TUMOR USING AN ANTI-PD-1 ANTIBODYJanuary 2023January 2024Abandon1211YesNo
18069489APPROACH FOR TREATMENT OF CANCER VIA IMMUNOMODULATION BY USING TALABOSTATDecember 2022October 2024Abandon2210NoNo
17955880TREATMENT OF CK8 POSITIVE CANCERS IN RELATION WITH K-RAS GENE STATUSSeptember 2022October 2024Abandon2401NoNo
17885255VACCINE COMPRISING EPITOPE OF HEAT SHOCK PROTEIN, AND USE THEREOFAugust 2022May 2025Allow3401YesNo
17870010METHODS AND COMPOSITIONS RELATING TO ANTI-PD1 ANTIBODY REAGENTSJuly 2022May 2025Allow3421YesNo
17860821PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERSJuly 2022September 2022Allow300YesNo
17843412PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERSJune 2022September 2022Allow300NoNo
17686238METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGENMarch 2022April 2025Allow3731YesNo
17587648METHOD FOR SUPPRESSING REGULATORY T CELL INFILTRATION BY CCR4 INHIBITION AND METHOD FOR TREATING CANINE NEOPLASTIC DISEASEJanuary 2022March 2024Allow2611NoNo
17587501COMPOSITIONS AND METHODS FOR TREATING CYTOKINE RELEASE SYNDROMEJanuary 2022December 2024Allow3421YesYes
17586676LIQUID BIOPSY TO DETECT CANCER EARLY AND SENSITIVELY IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1January 2022July 2024Allow2911YesNo
17547550COMPOSITIONS AND METHODS COMPRISING SFRP2 ANTAGONISTSDecember 2021August 2023Allow2001YesNo
17616134HUMANIZED TETRA-SPECIFIC OCTAVALENT ANTIBODY AGAINST CLOSTRIDIUM DIFFICILE TOXIN A AND BDecember 2021March 2024Allow2801YesNo
17613121ANTI-TYROSINASE ANTIBODY FOR INHIBITING TYROSINASE AND USE THEREOFNovember 2021February 2025Allow3900NoNo
17400308TARGETING TREATMENT FOR ADAM30 IN PATHOLOGICAL CELLSAugust 2021February 2024Allow3011YesNo
17381418TREATMENT OF T CELL LYMPHOMAJuly 2021June 2025Allow4721YesNo
17053008ANTIBODIES TO SARS-CORONAVIRUS (COVID-19) S1 SPIKE PROTEINJuly 2021May 2025Abandon5401NoNo
17423370COMBINATION PRODUCT FOR THE TREATMENT OF CANCERJuly 2021May 2025Abandon4611NoNo
17421202MODULATING BIOMARKERS SUCH AS SPP TO INCREASE TUMOR IMMUNITY AND IMPROVE THE EFFICACY OF CANCER IMMUNOTHERAPYJuly 2021March 2024Allow3211YesNo
17304909PERTUZUMAB PLUS TRASTUZUMAB FIXED DOSE COMBINATIONJune 2021January 2025Allow4321YesYes
17312368NOVEL APPROACH FOR TREATMENT OF CANCER USING IMMUNOMODULATIONJune 2021March 2025Abandon4510NoNo
17289623TREATMENT METHODSApril 2021January 2024Abandon3201NoNo
17237433NIDOGEN 1 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET OF HEPATOCELLULAR CARCINOMA, COMPOSITION AND METHODS THEREOFApril 2021June 2024Allow3831YesNo
17287358DOSINGApril 2021October 2024Abandon4201NoNo
17230435METHODS FOR NONINVASIVE DETECTION, DIAGNOSIS AND TREATMENT OF DISEASEApril 2021June 2025Abandon5031YesNo
17226233METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERSApril 2021January 2025Allow4511NoNo
16964133B7-H4 ANTIBODIES AND METHODS OF USE THEREOFMarch 2021December 2024Allow5311YesNo
17280493RECOMBINANT TYPE I CRISPR-CAS SYSTEM AND USES THEREOF FOR KILLING TARGET CELLSMarch 2021November 2024Allow4411NoNo
17280436RECOMBINANT TYPE I CRISPR-CAS SYSTEM AND USES THEREOF FOR GENOME MODIFICATION AND ALTERATION OF EXPRESSIONMarch 2021November 2024Allow4411NoNo
17271491NEOANTIGEN ENGINEERING USING SPLICE MODULATING COMPOUNDSFebruary 2021April 2025Abandon5011NoNo
17271018ENPP1 Polypeptides and Methods of Using SameFebruary 2021March 2025Allow4911YesNo
17264998MUSCLE-TARGETING COMPLEXES AND USES THEREOFFebruary 2021January 2024Abandon3601NoNo
17156392MOLECULAR SPATIAL MAPPING OF METASTATIC TUMOR MICROENVIRONMENTJanuary 2021March 2024Allow3821YesNo
17148227TARGETED DELIVERY OF THE ABRIN-A A-CHAIN TO CANCER CELLSJanuary 2021June 2024Abandon4121NoNo
16973400ANTI-HER3 Antibody and uses thereofDecember 2020January 2023Abandon2501YesNo
17103762COMPOSITIONS AND METHODS FOR CD20 IMMUNOTHERAPYNovember 2020July 2023Allow3201YesNo
17052553COMBINED INHIBITION OF PD-1/PD-L1, TGFB AND DNA-PK FOR THE TREATMENT OF CANCERNovember 2020August 2024Abandon4501NoNo
17052088ANTIBODIES, ACTIVATABLE ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOFOctober 2020August 2024Abandon4501NoNo
16964316CYTOKINE FUSION PROTEINSOctober 2020October 2024Allow5111YesNo
17051747CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOFOctober 2020September 2024Allow4711YesNo
17046998COMPOSITIONS AND METHODS FOR TREATING CANCEROctober 2020March 2023Allow2911NoNo
17045587NKG2D CHIMERIC ANTIGEN RECEPTORSOctober 2020June 2024Abandon4401NoNo
17036075MODULATING LACTOGENIC ACTIVITY IN MAMMALIAN CELLSSeptember 2020December 2024Allow5121YesNo
17040388ANTI-CD137 ANTIBODIES FOR COMBINATION WITH ANTI-PD-1 ANTIBODIESSeptember 2020February 2024Abandon4131NoNo
17027419PERSONALIZED CANCER IMMUNOTHERAPYSeptember 2020February 2025Allow5331NoNo
17019747ANTI-CEACAM ANTIBODIES AND USES THEREOFSeptember 2020December 2022Allow2701YesNo
16980807METHODS FOR REGULATING BREAST CANCERSSeptember 2020June 2023Abandon3311NoNo
16980294ANTI-CLAUDIN 18.2 ANTIBODIESSeptember 2020June 2022Allow2101NoNo
16979323TREATMENT OF HEAD AND NECK CANCERSeptember 2020June 2023Allow3310YesNo
16978976A RECOMBINANT PROTEIN COMPRISING A DOUBLE STRANDED RNA BINDING DOMAINSeptember 2020January 2024Abandon4031NoNo
16977126USE OF an anti-P-selectin antibodySeptember 2020June 2023Abandon3411NoNo
16971276LIGANDS TO GM-CSF OR GM-CSF-RECEPTOR FOR USE IN TREATMENT OF A HAEMATOLOGIC MALIGNANCY IN A PATIENT HAVING UNDERGONE ALLO-HCTAugust 2020August 2024Abandon4811NoNo
16997307VACCINE COMPRISING EPITOPE OF HEAT SHOCK PROTEIN, AND USE THEREOFAugust 2020May 2022Allow2101YesNo
16966968METHODS FOR TREATING CANCER WITH ANTI-PD-1 ANTIBODIESAugust 2020March 2025Allow5541YesYes
16944953DOSING REGIMEN FOR AN IDO INHIBITORJuly 2020April 2024Abandon4531NoNo
15733398PSMD9 INHIBITORS FOR THE TREATMENT OF HEPATIC LIPID DYSREGULATIONJuly 2020May 2024Allow4611NoNo
16957837CYTOTOXICITY-INDUCING THERAPEUTIC AGENTJune 2020March 2023Allow3211YesNo
16956112METHODS BASED ON THE DETECTION OF RAD51 FOCI IN TUMOR CELLSJune 2020February 2024Allow4331YesNo
16892912ANTI-PD-1/CD47 BISPECIFIC ANTIBODY AND APPLICATION THEREOFJune 2020January 2023Allow3211YesNo
16769567ANTI-DCLK1 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS OF USE THEREOFJune 2020October 2023Allow4112YesNo
16890835METHOD OF SCORING A SAMPLE COMPRISING TUMOR TISSUEJune 2020March 2023Allow3311NoNo
16768431TRPV6 INHIBITORS AND COMBINATION THERAPIES FOR TREATING CANCERSMay 2020May 2024Abandon4721YesYes
16765257SUICIDE GENE THERAPEUTIC AGENT FOR BRAIN TUMORS USING PLURIPOTENT STEM CELLMay 2020June 2024Allow4911YesNo
16762877IMMUNOGENIC COMPOSITIONS AND USES THEREFORMay 2020June 2023Abandon3720NoNo
16867125DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCERMay 2020May 2022Allow2501NoNo
16652827TUMOR AND METASTASIZING MARKERApril 2020September 2024Allow5331YesNo
16834981MARKER FOR GASTROINTESTINAL TUMORSMarch 2020May 2022Allow2510YesNo
16830810Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and DexamethasoneMarch 2020May 2023Abandon3820NoNo
16830585Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and DexamethasoneMarch 2020May 2023Abandon3820NoNo
16830909Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and PrednisoneMarch 2020May 2023Abandon3820NoNo
16830763Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Lenalidomide and DexamethasoneMarch 2020May 2023Abandon3820NoNo
16806674PATIENT PERSONALIZED CANCER VACCINEMarch 2020June 2023Abandon4011NoNo
16806664METHOD OF MAKING A PERSONALIZED CANCER VACCINEMarch 2020January 2025Abandon5950NoNo
16639441TREATMENT OF CK8 POSITIVE CANCERS IN RELATION WITH K-RAS GENE STATUSFebruary 2020November 2022Abandon3411NoNo
16781017Use of HE4 and other biochemical markers for assessment of endometrial and uterine cancersFebruary 2020April 2024Abandon5021NoYes
16635094RAPID TUMORIGENICITY SCREENING SYSTEMJanuary 2020February 2022Allow2510NoNo
16632101AN APPLICATION OF EXOSOME TBRII PROTEIN AS A MARKER IN THE PREPARATION OF BREAST CANCER DETECTION KITJanuary 2020February 2022Allow2510NoNo
16631041COMPOSITIONS AND METHODS FOR ENHANCING MACROPHAGE-MEDIATED ANTIBODY GUIDED CANCER CELL OR TUMOR ERADICATIONJanuary 2020January 2023Allow3621YesNo
16723716SOURCE OF ORIGIN DECONVOLUTION BASED ON METHYLATION FRAGMENTS IN CELL-FREE DNA SAMPLESDecember 2019December 2024Allow6041YesNo
16716815TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITORDecember 2019March 2023Allow3911YesNo
16621197DIAGNOSTIC, PROGNOSTIC, AND MONITORING METHODS FOR SOLID TUMOR CANCERSDecember 2019January 2023Allow3820YesNo
16617725METHODS OF TREATING A TUMOR USING AN ANTI-PD-1 ANTIBODYNovember 2019May 2022Allow3020NoNo
16617074ANTI-DOUBLECORTIN-LIKE KINASE 1 ANTIBODIES AND METHODS OF USENovember 2019January 2023Allow3711YesNo
16617229COMBINATION THERAPIES FOR TREATING CANCERSNovember 2019April 2024Allow5331YesNo
16616574TREATMENT OF LAG-3 POSITIVE TUMORSNovember 2019July 2023Allow4432NoNo
16687763TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMANovember 2019October 2023Abandon4711NoNo
16613673METHOD FOR SUPPRESSING REGULATORY T CELL INFILTRATION BY CCR4 INHIBITION AND METHOD FOR TREATING CANINE NEOPLASTIC DISEASENovember 2019June 2022Abandon3111NoNo
16612363COMBINATION THERAPIES FOR TREATING CANCERNovember 2019June 2023Allow4331YesNo
16611018INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETONovember 2019September 2024Allow5911YesNo
16608275METHODS AND COMPOSITIONS RELATING TO ANTI-PD1 ANTIBODY REAGENTSOctober 2019April 2022Allow3011NoNo
16597856Optimization of Gene Sequences for Protein ExpressionOctober 2019November 2022Allow3710YesNo
16499995Humanized Anti-TPBG Antibody, Preparation Method Therefor, Conjugate Thereof, and ApplicationsOctober 2019October 2022Allow3711YesNo
16499094CANCER STEM CELLSeptember 2019September 2022Abandon3601NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SULLIVAN, DENNIS JOHN.

Strategic Value of Filing an Appeal

Total Appeal Filings
5
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
5
(100.0%)
Filing Benefit Percentile
0.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SULLIVAN, DENNIS JOHN - Prosecution Strategy Guide

Executive Summary

Examiner SULLIVAN, DENNIS JOHN works in Art Unit 1642 and has examined 110 patent applications in our dataset. With an allowance rate of 59.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner SULLIVAN, DENNIS JOHN's allowance rate of 59.1% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SULLIVAN, DENNIS JOHN receive 1.45 office actions before reaching final disposition. This places the examiner in the 33% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SULLIVAN, DENNIS JOHN is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +53.0% benefit to allowance rate for applications examined by SULLIVAN, DENNIS JOHN. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 25.3% of applications are subsequently allowed. This success rate is in the 30% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 92.9% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.